At­las, F-Prime launch K36 Ther­a­peu­tics to ad­vance on­col­o­gy mol­e­cule for elu­sive epi­ge­net­ic tar­get

4 years ago
Financing
Startups

FDA ad­comm votes unan­i­mous­ly against Reata's po­ten­tial Al­port syn­drome treat­ment

4 years ago
R&D
FDA+

Of­fer­ing a long-await­ed op­tion for the un­vac­ci­nat­ed, FDA au­tho­rizes As­traZeneca's long-act­ing pre­ven­ta­tive an­ti­body

4 years ago
FDA+
Coronavirus

Video: Hear from End­points' 2021 Women in Bio­phar­ma R&D hon­orees and lis­ten in on our pan­el dis­cus­sion on break­ing ...

4 years ago
Special

No­var­tis drafts artist No­ma Bar's bold vi­su­als to ex­plain com­plex MDS blood can­cer

4 years ago
Pharma
Marketing

FDA+ roundup: Re­pub­li­cans will be key for Rob Calif­f's con­fir­ma­tion; Janet Wood­cock and Mar­garet Ham­burg talk FDA and ...

4 years ago
FDA+

Omi­cron is a test for the next pan­dem­ic. Will the world keep mak­ing the same mis­takes?

4 years ago
Coronavirus
In Focus

So­tio part­ners with Mer­ck to test lead can­di­date with Keytru­da; DC's KeifeRx rais­es $6M in Se­ries A — and brings on ...

4 years ago
News Briefing

Ex-FDA chief Stephen Hahn lands an­oth­er new gig, this time as CEO of a can­cer test­ing start­up

4 years ago
Financing
FDA+

Biotech up­start gets $50M to test new virus-based ther­a­pies against sol­id tu­mors

4 years ago
Deals
Manufacturing

Mer­ck KGaA's ven­ture arm is ready to make new in­vest­ments, rais­ing more than $675M to get things go­ing

4 years ago
Financing
Pharma

New stud­ies in­di­cate mR­NA vac­cines pro­vide lim­it­ed pro­tec­tion against Omi­cron, but boost­ers and new shots may be ...

4 years ago
R&D
Coronavirus

Ac­cuser fires back at MIT sci­en­tist David Saba­tini's claims he was false­ly ac­cused of sex­u­al ha­rass­ment

4 years ago
People

Phar­ma men­ace Mar­tin Shkre­li's old com­pa­ny to pay up to $40M to states for Dara­prim price goug­ing

4 years ago
Pharma

Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

4 years ago
Financing
China

On the heels of Se­ries A, Nom­ic will join Broad In­sti­tute con­sor­tium and ex­pand ac­cess to plat­form

4 years ago
Manufacturing

New­path Part­ners kicks off $350M fund with a wun­derkind hold­ing the bag and an all-star sci­en­tif­ic team wait­ing in ...

4 years ago
Financing
Startups

Mar­ket­ingRx Matchup: How Ab­b­Vie and Bio­haven ads rank in head-to-head mi­graine chal­lenge

4 years ago
Pharma
Marketing

Q&A: Organon chief com­mu­ni­ca­tions of­fi­cer Wendy Lund talks about the Mer­ck spin­off, women’s health and why it ...

4 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: Pfiz­er re-ups pneu­mo­nia ads as Mer­ck threat looms; Re­al Chem­istry founder CEO Jim Weiss steps ...

4 years ago
Pharma
Marketing

Mer­ck pumps the brakes on two more PhI­II tri­als for its lead an­ti-HIV drug

4 years ago
R&D

vTv Ther­a­peu­tics cuts 65% of em­ploy­ees in shake­up; Freenome bags $300M in Se­ries D to ex­pand mul­ti­omics plat­form

4 years ago
News Briefing

Lon­don AI-fo­cused Benev­o­len­tAI go­ing pub­lic in Eu­rope via $438M SPAC deal

4 years ago
Financing
AI

Aca­dia touts late-stage win for its Rett syn­drome drug, edg­ing out a lead against its com­peti­tors

4 years ago
R&D
First page Previous page 604605606607608609610 Next page Last page
A service from the Financial Times